Basic Daonil Information

• INN (International Nonproprietary Name): Glyburide (also known as glibenclamide in several international markets).
• Brand Names Available In United Kingdom: not specified.
• ATC Code: A10BB09.
• Forms & Dosages: Tablets 1.25 mg, 2.5 mg and 5 mg; no parenteral or topical forms marketed.
• Manufacturers In United Kingdom: generics supplied globally by Mylan, Teva and Sandoz (local UK brand listings vary).
• Registration Status In United Kingdom: marketed as glibenclamide generics and available as a prescription medicine.
• OTC / Rx Classification: Prescription only (Rx).

Key Findings From Recent Trials

Are you worried about how effective and safe daonil really is compared with modern diabetes drugs?

Recent clinical trials and pooled observational analyses from 2022–2025 reinforce two consistent themes about glyburide (glibenclamide/Daonil).

First, glyburide’s glucose‑lowering efficacy for fasting and overall glycaemia is broadly comparable to older sulfonylureas.

Second, the risk of hypoglycaemia—especially prolonged or severe episodes—is consistently higher compared with metformin and many newer classes.

Cardiovascular outcomes do not appear to favour glyburide compared with newer agents such as GLP‑1 receptor agonists and SGLT2 inhibitors.

Observational cohorts flagged increased hypoglycaemia admissions in elderly patients and those with renal impairment.

For UK practice, prescribers increasingly favour metformin first line and often choose gliclazide rather than glyburide when a sulfonylurea is required.

Regulatory context: the Micronase brand was withdrawn from some US markets historically, while generics remain widely available internationally.

If you search clinic notes for glibenclamide trials or sulfonylurea safety you will find repeated emphasis on hypoglycaemia risk.

Clinical Mechanism Of Action

Layman’s Explanation

Wondering how daonil lowers blood sugar?

Glyburide nudges the pancreas to release more insulin, so your body lowers blood glucose by increasing native insulin secretion.

This is why the drug can work well for type 2 diabetes but can cause low blood sugar if meals are missed.

Scientific Breakdown

Glyburide is a second‑generation sulfonylurea (ATC A10BB09).

It binds the SUR1 subunit of ATP‑sensitive potassium (KATP) channels on pancreatic β‑cells.

Binding closes KATP channels, depolarising the membrane and triggering opening of voltage‑gated calcium channels.

Calcium influx then triggers insulin vesicle exocytosis and increased insulin release.

Beta‑Cell Electrophysiology

SUR1 binding → KATP channel inhibition.

Membrane depolarisation → voltage‑dependent calcium entry → insulin release.

Pharmacokinetics Basics

Glyburide is given orally as tablets 1.25–5 mg.

Absorption can be variable with food, and the drug undergoes hepatic metabolism with renal elimination of metabolites.

Prolonged insulinotropic action explains the higher hypoglycaemia risk, particularly in elderly people or those with renal impairment.

Typical maintenance doses range from 1.25 mg to 20 mg per day.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Do clinicians still prescribe Daonil in the UK and for what?

Glyburide (glibenclamide/Daonil) is indicated for improving glycaemic control in adults with type 2 diabetes where diet, exercise and first‑line agents are insufficient.

In the UK, gliclazide and other sulfonylureas are commonly preferred to glyburide because of a more favourable hypoglycaemia profile.

Glyburide remains available as generic glibenclamide tablets and may be prescribed, but it is less frequently chosen than gliclazide.

Notable Off‑Label Trends

Rare specialist uses include treatment of neonatal hyperinsulinaemia under specialist supervision and with bespoke monitoring.

Use in pregnancy and breastfeeding is generally contraindicated because glyburide crosses the placenta and can cause neonatal hypoglycaemia.

Formulations: tablets typically 1.25 mg, 2.5 mg and 5 mg; maximum 20 mg/day.

Dosage Strategy

General Dosing

How should daonil be started and titrated?

Typical initiation in adults is 2.5–5 mg once daily, then titrated slowly to effect.

Maintenance range is 1.25–20 mg per day, given once daily or divided into two doses.

Maximum recommended dose is 20 mg/day.

Condition‑Specific Dosing

When added to metformin start low (for example 2.5 mg) then up‑titrate cautiously to avoid hypoglycaemia.

Elderly patients should start at the lowest available dose (1.25 mg) with close monitoring.

Glyburide is contraindicated in significant renal impairment because active metabolites can accumulate and prolong hypoglycaemia.

In hepatic impairment use a lower starting dose and monitor glucose closely as metabolism may be affected.

Prescribing tip: align dosing with breakfast to reduce fasting hypoglycaemia and educate patients not to double missed doses.

Safety Protocols

Contraindications

Who must not take daonil?

Absolute contraindications include type 1 diabetes, diabetic ketoacidosis and known hypersensitivity to sulfonylureas.

Significant renal or hepatic impairment and pregnancy or breastfeeding are absolute exclusions due to safety concerns.

Adverse Effects

The most clinically significant adverse event is hypoglycaemia, which may be prolonged because of the drug’s long insulinotropic action.

Other common effects are nausea, vomiting, dyspepsia, mild skin rash, headache and dizziness.

Monitor for weight gain and rare haematological or liver‑enzyme abnormalities.

Safety checklist for prescribers: baseline renal and liver function tests, medication reconciliation for interactions, and a clear plan for hypoglycaemia rescue and follow‑up reviews.

Interaction Mapping

Food Interactions

Can you eat normally while taking daonil?

Food can delay absorption, but the main issue is irregular meals or missed calories increasing hypoglycaemia risk because glyburide stimulates insulin regardless of recent intake.

Advise patients to maintain consistent meal timing and carry glucose sources.

Drug Combinations To Avoid

High‑risk combinations include other hypoglycaemic drugs such as insulin or meglitinides due to additive hypoglycaemia.

CYP inhibitors (some azole antifungals, macrolides) can increase glyburide levels and hypoglycaemia risk.

CYP inducers (rifampicin, certain anticonvulsants) may reduce glyburide effect.

Medicines that displace protein binding (salicylates, sulfonamides) may increase free drug concentration.

Beta‑blockers can mask hypoglycaemia symptoms, so take care in cardiac patients.

Patient Experience Analysis

Survey Data

What do patients say about using Daonil?

Surveys and service evaluations show effective glycaemic control but frequent concern about hypoglycaemia, particularly nocturnal episodes and longer recovery in older adults.

Fear of low blood sugars affects adherence and prompts extra self‑monitoring when doses change.

Forum Trends

On patient forums, some users report good control on low doses while many express a preference for alternatives with lower hypoglycaemia risk.

Common patient queries reference brand names such as Micronase or ask about switching to gliclazide or glibenclamide/metformin combinations.

Shared decision‑making is recommended, and practical counselling should include a hypoglycaemia action plan and supply of fast‑acting carbohydrate.

Distribution & Pricing Landscape

How easily can you get daonil and what will it cost?

Glyburide is widely manufactured as generics by companies including Teva, Mylan and Sandoz and is typically sourced as glibenclamide in the UK market.

Tablet strengths are commonly 1.25 mg, 2.5 mg and 5 mg, packaged in blister cards or bottles.

Generics are low cost and, within an NHS context, sulfonylureas are generally inexpensive compared with newer therapies.

Buyers should ensure suppliers are MHRA‑approved and check the product monograph for local licence details.

In our online pharmacy, daonil is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

Which drugs are commonly chosen instead of daonil?

Key alternatives include metformin, gliclazide/glipizide (other sulfonylureas), repaglinide, DPP‑4 inhibitors, GLP‑1 receptor agonists and SGLT2 inhibitors.

Metformin remains first line in the UK and is usually preferred for its low hypoglycaemia risk and weight‑neutral effect.

Pros And Cons

• Glyburide: Pros — effective, oral, low unit cost. Cons — higher hypoglycaemia risk and renal cautions.
• Gliclazide: Pros — lower hypoglycaemia risk among sulfonylureas and commonly preferred in UK practice.
• Metformin: Pros — first‑line, low hypoglycaemia risk. Cons — gastrointestinal side effects and renal restrictions at reduced eGFR thresholds.

Regulatory Status

Is daonil licensed and regulated?

Glyburide (INN glyburide; often marketed internationally as glibenclamide) is registered globally as a prescription‑only medicine and classified under ATC A10BB09.

Micronase was a historic US brand that has been discontinued, while generics remain FDA‑approved in the US and available elsewhere.

In the UK it is available as glibenclamide generics and subject to MHRA oversight and Yellow Card adverse‑event reporting.

Clinicians should consult local SPCs for country‑specific licence details and pharmacovigilance updates from manufacturers such as Teva, Mylan and Sandoz.

Consolidated FAQ

People often want quick answers about daonil—here are the essentials.

Q: What is Daonil?

A: Daonil is an international trade name associated with glyburide/glibenclamide, a sulfonylurea for type 2 diabetes; tablets are typically 1.25–5 mg and the medicine is prescription only.

Q: Is it safe for the elderly?

A: Start at the lowest dose (for example 1.25 mg) and monitor closely because hypoglycaemia risk is higher in older adults.

Q: Can I take it with metformin?

A: Yes, glyburide is commonly used as an add‑on to metformin starting at a low dose such as 2.5 mg with cautious titration.

Q: Is it available in the UK?

A: Yes, glyburide is available as generic glibenclamide in the UK but is less commonly prescribed than gliclazide.

Q: What if I miss a dose?

A: Take as soon as remembered unless it is near the next dose; do not double up.

Q: What about pregnancy?

A: Contraindicated—glyburide crosses the placenta and can cause neonatal hypoglycaemia.

Q: Overdose?

A: Severe hypoglycaemia is the main danger—seek emergency care and give glucose or dextrose as needed.

Visual Guide

Labelling & Packaging

How should clinicians and pharmacists recognise daonil packages?

Packaging is typically blister packs or bottles with tablet strengths 1.25 mg, 2.5 mg and 5 mg clearly marked.

Micronase historically used FD&C Red No. 40 for 2.5 mg and FD&C Blue No. 1 for 5 mg; generic colourants now vary.

Inactive ingredients listed in older Micronase leaflets include microcrystalline cellulose, magnesium stearate and talc—check current product leaflets for specific excipients.

Patient Charts And Monitoring Aids

Useful visual aids include a hypoglycaemia action plan card, a dosage titration chart and a renal/hepatic monitoring timeline indicating baseline and periodic checks.

Suggested clinician infographics: a mechanism schematic (KATP channel to insulin release), a risk matrix showing age/renal impairment versus hypoglycaemia likelihood, and a bar chart comparing hypoglycaemia risk to metformin and newer agents.

Storage & Transport

How should daonil be stored and sent?

Store glyburide/glibenclamide tablets at controlled room temperature, ideally 20–25°C, and protect from moisture.

Keep medication in original packaging to retain labelling and stability information.

Community pharmacies should avoid storing in high‑humidity areas such as bathrooms and should keep supplies in a temperature‑controlled dispensary.

Transport packages should buffer temperature extremes for postal deliveries, and suppliers should supply certificates of analysis for international procurement.

Disposal of unused tablets should follow UK pharmacy take‑back protocols.

Guidelines For Proper Use

Prescriber Checklist

What should prescribers document and check before issuing daonil?

Confirm the diagnosis of type 2 diabetes and review renal and hepatic function before starting treatment.

Assess hypoglycaemia risk factors such as age, comorbidities and polypharmacy and document the rationale if choosing glyburide over alternatives such as gliclazide.

Start at a low dose and schedule follow‑up appointments to review fasting glucose, HbA1c and adverse events.

Do not exceed 20 mg/day and ensure shared decision‑making with the patient about risks and benefits.

Patient Counselling Points

Counsel patients to take the tablet with or shortly before breakfast to reduce fasting lows.

Explain hypoglycaemia symptoms—sweating, tremor, confusion—and advise carrying fast‑acting carbohydrate and informing family or carers.

Advise against alcohol with irregular meals and stress that missed doses should not be doubled.

Pregnancy or breastfeeding require alternative therapy planning and contraception discussion if glyburide is currently used.

Delivery Across United Kingdom